Get full access to one story every week, and to summaries of all other stories. Just create a free account

Suraksha P

Suraksha writes on Healthcare and Pharma. She has been a journalist for five years, reporting for The New Indian Express in Bengaluru and Chennai, and The Times of India, Delhi. In her previous stints she has written on health, civic issues and education. She investigated cover up of corruption in the state health department’s think tank, narrated harrowing tales of women who underwent unwarranted hysterectomies, and wrote about how loss of biometrics came in the way of Leprosy patients getting an Aadhaar card and thereby pension. She can be reached at suraksha at the-ken dot com.

17 Articles published

Top Comments by Suraksha P

Tata Health: Many tests but short on diagnosis

Hi Rajiv, Thank you for writing in. As the story mentions, catalogue is the most crucial part for a pharmacy business as it lists prices etc. Also, our sources tell us that Pharmeasy wanted to communicate with customers who they are providing medicines for since they are the pharmacy partners but TDH allegedly did not have the infrastructure to facilitate this communication. The story has been corrected and updated to say that Rs 36 crore was their revenue from operations. Sorry for the error. Rs 94 crore is 11.31% of TIL's turnover that TDH contributes to according to its financials.

Suraksha P

Post J&J fiasco, India's 3D printed implants are still market misfits

Hi Rajiv, Thanks for writing in. a) As the article explains unlike in the West, 3D printed hip implants are prescribed for complex revision surgeries and not for primary surgeries. So, when hip implants fail after 10-15 years, that is when 3D printed ones are prescribed if there are complications that a standard off-the-shelf implant can't cater to. b) The manufacturers are still not sure if customisable implants will come under the scanner as it is a different ball game. Also, like many other medical device manufacturers they are opposed to being brought under the CDSCO as it takes much longer to develop drugs than medical devices.That is why the NITI Aayog floated a draft bill for a separate regulator for medical devices. They want IITs to regulate medical device manufacturers. So they will adopt a wait and watch approach for now till December 1 for more clarity.

Suraksha P

Whey out: Protein-deficient India big on importing supplements

Hi Suresh, Your feedback is noted. However, may I point out that the nutrition and wellness consultant quoted here isn't talking about making whey protein a primary source, she is talking about its effectiveness as a supplement for people who are not body builders or don't work out for more than an hour. Also, a trainer has given his opinion on the product after personally using it. So, while there are men who want to build muscle who vouch for it, there are also gym trainers and nutritionists who don't recommend it.

Suraksha P

Stories by Suraksha P